High Tower Advisors, LLC Cue Biopharma, Inc. Transaction History
High Tower Advisors, LLC
- $68.3 Billion
- Q3 2024
A detailed history of High Tower Advisors, LLC transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 83,284 shares of CUE stock, worth $88,281. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,284
Previous 83,284
-0.0%
Holding current value
$88,281
Previous $103,000
38.83%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CUE
# of Institutions
52Shares Held
14.1MCall Options Held
14.4KPut Options Held
2.6K-
Bleichroeder LP New York, NY5MShares$5.3 Million1.28% of portfolio
-
Slate Path Capital LP New York, NY2.4MShares$2.55 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.03MShares$2.15 Million0.0% of portfolio
-
Black Rock Inc. New York, NY757KShares$802,1400.0% of portfolio
-
Geode Capital Management, LLC Boston, MA509KShares$539,3560.0% of portfolio
About Cue Biopharma, Inc.
- Ticker CUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,381,700
- Market Cap $37.5M
- Description
- Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...